Vitamin K2 Best Dose for Osteoporosis in Women
Quick Summary: This study looked at how different doses of vitamin K2 (a form called menaquinone-4 or MK-4) affect a bone health marker in women with osteoporosis. It found that 15 mg per day worked best to improve bone markers, with no extra benefit from doubling the dose. This could help women manage bone loss more effectively.
What The Research Found
Researchers tested vitamin K2 to see how much it takes to help with bone health in women with osteoporosis. Vitamin K2 helps turn a protein called osteocalcin into its active form, which supports strong bones. The inactive form, called undercarboxylated osteocalcin (ucOC), is a sign of poor bone turnover.
Key results showed:
- Low dose (1.5 mg/day): Cut ucOC by 12%.
- Medium dose (5 mg/day): Cut ucOC by 28%.
- Higher dose (15 mg/day): Cut ucOC by 50%—the biggest improvement.
- Highest dose (30 mg/day): Cut ucOC by 48%, almost the same as 15 mg, so no real extra gain.
Active osteocalcin (cOC) levels rose with these changes, meaning better bone building. The sweet spot seems to be 15 mg/day for max effect without overdoing it.
Study Details
- Who was studied: 60 Japanese women aged 60-80 with osteoporosis, mostly after menopause when bone loss speeds up.
- How long: 12 weeks, a short-term look to spot quick changes in bone markers.
- What they took: Oral vitamin K2 (MK-4) supplements at 0 mg (no treatment group), 1.5 mg, 5 mg, 15 mg, or 30 mg per day. Higher doses were split, like 15 mg twice a day, taken with meals for better absorption. They measured blood levels of ucOC at the start and end.
What This Means For You
If you're a woman over 60 with osteoporosis or at risk, this suggests vitamin K2 could be a helpful add-on to your routine. Aim for around 15 mg of MK-4 daily from supplements or foods like fermented soy (natto) or cheese to support bone strength—talk to your doctor first, especially if on blood thinners.
- Daily tip: Pair it with vitamin D and calcium for better results, as they work together for bones.
- Why it matters: Lower ucOC means your body might be better at using calcium to build bone, potentially slowing osteoporosis.
- Next step: Get a bone density scan and discuss K2 with your healthcare provider to see if it fits your needs.
Study Limitations
This was an observational study, so it shows links but not proven cause-and-effect—longer trials are needed for real-world bone fracture prevention. It only included Japanese women, so results might differ for other groups like men or non-Asian women. No side effects were noted, but always check with a pro before starting supplements.
Technical Analysis Details
Key Findings
The study demonstrated that higher doses of vitamin K2 (menaquinone-4, MK-4) significantly reduced levels of undercarboxylated osteocalcin (ucOC), a biomarker of bone turnover, in postmenopausal women with osteoporosis. A dose of 15 mg twice daily showed the maximal therapeutic effect, with no further reduction at 30 mg/day, suggesting a plateau in efficacy.
Study Design
This was an observational dose-response study conducted over 12 weeks. It included 60 Japanese women (ages 60–80) with osteoporosis, divided into five groups receiving varying MK-4 doses (0, 1.5, 5, 15, or 30 mg/day). The primary outcome was serum ucOC levels, measured at baseline and post-intervention.
Dosage & Administration
MK-4 was administered orally in daily doses of 0 mg (control), 1.5 mg, 5 mg, 15 mg, or 30 mg. Participants took supplements with meals to enhance absorption. The 15 mg and 30 mg groups received split doses (e.g., 15 mg twice daily).
Results & Efficacy
- ucOC reduction:
- 1.5 mg/day: 12% decrease (p=0.03 vs. baseline).
- 5 mg/day: 28% decrease (p<0.01).
- 15 mg/day: 50% decrease (p<0.001).
- 30 mg/day: 48% decrease (p=0.12 vs. 15 mg/day).
- The 15 mg/day dose achieved the greatest statistically significant reduction in ucOC, with no additional benefit at 30 mg/day. Carboxylated osteocalcin (cOC) levels increased proportionally, indicating improved bone mineralization.
Limitations
- Sample demographics: Limited to Japanese women; findings may not generalize to other populations.
- Observational design: Cannot establish causality or long-term clinical outcomes (
Original Study Reference
Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis.
Source: PubMed
Published: 2020
📄 Read Full Study (PMID: 30816822)